Salvage temozolomide for prior temozolomide responders Journal Article
| Authors: | Franceschi, E.; Omuro, A. M. P.; Lassman, A. B.; Demopoulos, A.; Nolan, C.; Abrey, L. E. |
| Article Title: | Salvage temozolomide for prior temozolomide responders |
| Abstract: | BACKGROUND. Temozolomide (TMZ) often is used as adjuvant or first-line therapy for patients with glioma. Because of potential hematologic complications, it usually is discontinued after 12-18 cycles, even in responders. Subsequent salvage therapies are reported to have limited efficacy at the time of disease recurrence. In the current study, the authors assessed the outcome and complications of reusing TMZ at the time of disease recurrence in patients who previously responded to treatment. METHODS. A retrospective review of patients with recurrent/progressive glioma who had a history of response to TMZ and were treated with the same agent at the time of disease recurrence was conducted. RESULTS. Fourteen patients were identified (8 men and 6 women). The median age of the patients was 56 years (range, 25-67 yrs) at the time of diagnosis; 9 patients had glioblastoma, 3 had anaplastic astrocytoma, and 2 patients had low-grade oligodendroglioma. No patient developed disease progression while receiving the initial TMZ treatment. At the time of the initial disease recurrence, 13 patients were readministered TMZ. One patient received TMZ at the time of second disease recurrence. All patients were assessed for radiographic response. Objective response or stable disease was achieved in 6 patients (43%; 95% confidence interval [95% CI], 21-67%) and the 6-month progression-free survival was 36% (95% CI, 16-61%). CONCLUSIONS. TMZ was found to be well tolerated and effective in this setting, suggesting that repeat use of TMZ in previous responders warrants further investigation. © 2005 American Cancer Society. |
| Keywords: | adult; cancer survival; clinical article; treatment outcome; aged; middle aged; survival analysis; leukemia; retrospective studies; drug tolerability; fatigue; neutropenia; review; salvage therapy; cancer growth; diarrhea; drug efficacy; drug withdrawal; cancer adjuvant therapy; chemotherapy; temozolomide; recurrent cancer; brain tumor; glioma; brain neoplasms; dacarbazine; blood toxicity; recurrence; retrospective study; glioblastoma; antineoplastic agents, alkylating; oligodendroglioma; astrocytoma; myelodysplasia; brain radiography |
| Journal Title: | Cancer |
| Volume: | 104 |
| Issue: | 11 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2005-12-01 |
| Start Page: | 2473 |
| End Page: | 2476 |
| Language: | English |
| DOI: | 10.1002/cncr.21564 |
| PUBMED: | 16270316 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 45" - "Export Date: 24 October 2012" - "CODEN: CANCA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
111Lassman -
204Omuro -
278Abrey -
59Nolan -
13
Demopoulos
Related MSK Work